Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant androgen suppression plus docetaxel after radical prostatectomy for high-risk prostate cancer
ChiCTR1800016445Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Prostate-specific antigen. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR1800016445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016445.